Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofen + diphenhydramine modified-release
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ibuprofen + diphenhydramine modified-release is a combination drug product developed by Overseas Pharmaceuticals, Ltd. for the treatment of pain and associated insomnia. It consists of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, and diphenhydramine hydrochloride, a first-generation H1 receptor antagonist used for its sedative properties. The formulation is designed as a modified-release tablet to provide sustained relief and aid sleep. Development reached Phase 1 clinical trials in China, where it was compared to Motrin IB and Benadryl, but the project was suspended in 2018 due to strategic considerations by the sponsor.
- Other names
- Compound ibuprofen polyrelease tabletsIbuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on ibuprofen + diphenhydramine modified-release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofen + diphenhydramine modified-release.